Vanda Pharmaceuticals (NASDAQ: VNDA) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.
Valuation & Earnings
This table compares Vanda Pharmaceuticals and Leap Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vanda Pharmaceuticals||$165.08 million||4.83||-$15.56 million||($0.35)||-45.20|
|Leap Therapeutics||N/A||N/A||-$29.72 million||($3.31)||-2.76|
This table compares Vanda Pharmaceuticals and Leap Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Vanda Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.42, suggesting that its share price is 142% less volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Vanda Pharmaceuticals and Leap Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vanda Pharmaceuticals presently has a consensus target price of $22.17, indicating a potential upside of 40.12%. Given Vanda Pharmaceuticals’ higher possible upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Leap Therapeutics.
Institutional & Insider Ownership
81.0% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Leap Therapeutics shares are owned by institutional investors. 7.6% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 58.7% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Vanda Pharmaceuticals beats Leap Therapeutics on 9 of the 11 factors compared between the two stocks.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.